Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | KAT7 | O95251 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870776 | 1.00 | ACKR3 (0.50) | ACKR3OPRD1KDM1AACHEUSP30 | |
| SCHEMBL5870788 | 1.00 | ACKR3 (0.50) | ACKR3OPRD1KDM1AACHEUSP30 | |
| SCHEMBL5870830 | 0.90 | ACHE (0.56) | ACKR3KDM1AACHEUSP30BCHE | |
| SCHEMBL5870690 | 0.90 | ACKR3 (0.49) | ACKR3KDM1AUSP30BCHEHTR6 | |
| SCHEMBL5870694 | 0.90 | PTPRB (0.52) | ACKR3KDM1AUSP30BCHEHTR6 | |
| SCHEMBL5870863 | 0.89 | NAMPT (0.48) | OPRD1ACHEJAK2JAK1KDM4E | |
| SCHEMBL5870948 | 0.88 | CYP2C9 (0.46) | ACKR3KDM1AFEN1BACE1CTSD | |
| SCHEMBL3089163 | 0.87 | KDM4E (0.55) | OPRD1ACHEKDM4EPKMPTPRB | |
| SCHEMBL6500523 | 0.87 | ACKR3 (0.52) | ACKR3KDM1AUSP30BCHEHTR6 | |
| SCHEMBL5870963 | 0.86 | KAT7 (0.46) | ACKR3KDM1AUSP30BCHEHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129228-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | CUNY GREGORY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-6677332-B1 | AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS | SEPRACOR, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6645980-B1 | Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals | SEPRACOR INC. | 2003-11-11 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | ACKR3 248/4885OPRD1 9/4885KDM1A 4501/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | ACKR3 248/4885OPRD1 9/4885KDM1A 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.